Rifaximin and propranolol combination therapy is more effective than propranolol monotherapy for the reduction of portal pressure: An open randomized controlled pilot study

Yoo Li Lim, Moonyoung Kim, Yoon Ok Jang, Soonkoo Baik, Sang Ok Kwon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background/Aims: Non-selective beta blockers (NSBBs) are currently the only accepted regimen for preventing portal hypertension (PHT)-related complications. However, the effect of NSBBs is insufficient in many cases. Bacterial translocation (BT) is one of the aggravating factors of PHT in cirrhosis; therefore, selective intestinal decontamination by rifaximin is a possible therapeutic option for improving PHT. We investigated whether the addition of rifaximin to pro-pranolol therapy can improve hepatic venous pressure gradient (HVPG) response. Methods: Sixty-four cirrhosis patients were randomly assigned to propranolol monotherapy (n=48) versus rifaximin and propranolol combination therapy (n=16). Baseline and post-Treatment HVPG values, BT-related markers (lipopolysaccharide [LPS], LPS-binding protein [LBP], interleukin-6 [IL-6], and tumor necrosis factor α [TNF-α]), serological data, and adverse event data were collected. HVPG response rate was the primary endpoint. Results: Combination therapy was associated with better HVPG response rates than monotherapy (56.2% vs 87.5%, p=0.034). In combination therapy, posttreatment BT-related markers were significantly decreased (LPS, p=0.005; LBP, p=0.005; IL-6, p=0.005; TNF-α, p=0.047). Conclusions: Rifaximin combination therapy showed an additive effect in improving PHT compared to propranolol monotherapy. These pilot data suggest that the addition of rifaximin to NSBBs could be a good therapeutic option for overcoming the limited effectiveness of NSBBs.

Original languageEnglish
Pages (from-to)702-710
Number of pages9
JournalGut and Liver
Volume11
Issue number5
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

rifaximin
Portal Pressure
Propranolol
Venous Pressure
Portal Hypertension
Bacterial Translocation
Liver
Therapeutics
Lipopolysaccharides
Interleukin-6
Fibrosis
Decontamination
Tumor Necrosis Factor-alpha

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{ca7eee16e9e74e90a9809324d8b18f17,
title = "Rifaximin and propranolol combination therapy is more effective than propranolol monotherapy for the reduction of portal pressure: An open randomized controlled pilot study",
abstract = "Background/Aims: Non-selective beta blockers (NSBBs) are currently the only accepted regimen for preventing portal hypertension (PHT)-related complications. However, the effect of NSBBs is insufficient in many cases. Bacterial translocation (BT) is one of the aggravating factors of PHT in cirrhosis; therefore, selective intestinal decontamination by rifaximin is a possible therapeutic option for improving PHT. We investigated whether the addition of rifaximin to pro-pranolol therapy can improve hepatic venous pressure gradient (HVPG) response. Methods: Sixty-four cirrhosis patients were randomly assigned to propranolol monotherapy (n=48) versus rifaximin and propranolol combination therapy (n=16). Baseline and post-Treatment HVPG values, BT-related markers (lipopolysaccharide [LPS], LPS-binding protein [LBP], interleukin-6 [IL-6], and tumor necrosis factor α [TNF-α]), serological data, and adverse event data were collected. HVPG response rate was the primary endpoint. Results: Combination therapy was associated with better HVPG response rates than monotherapy (56.2{\%} vs 87.5{\%}, p=0.034). In combination therapy, posttreatment BT-related markers were significantly decreased (LPS, p=0.005; LBP, p=0.005; IL-6, p=0.005; TNF-α, p=0.047). Conclusions: Rifaximin combination therapy showed an additive effect in improving PHT compared to propranolol monotherapy. These pilot data suggest that the addition of rifaximin to NSBBs could be a good therapeutic option for overcoming the limited effectiveness of NSBBs.",
author = "Lim, {Yoo Li} and Moonyoung Kim and Jang, {Yoon Ok} and Soonkoo Baik and Kwon, {Sang Ok}",
year = "2017",
month = "9",
day = "1",
doi = "10.5009/gnl16478",
language = "English",
volume = "11",
pages = "702--710",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "5",

}

TY - JOUR

T1 - Rifaximin and propranolol combination therapy is more effective than propranolol monotherapy for the reduction of portal pressure

T2 - An open randomized controlled pilot study

AU - Lim, Yoo Li

AU - Kim, Moonyoung

AU - Jang, Yoon Ok

AU - Baik, Soonkoo

AU - Kwon, Sang Ok

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background/Aims: Non-selective beta blockers (NSBBs) are currently the only accepted regimen for preventing portal hypertension (PHT)-related complications. However, the effect of NSBBs is insufficient in many cases. Bacterial translocation (BT) is one of the aggravating factors of PHT in cirrhosis; therefore, selective intestinal decontamination by rifaximin is a possible therapeutic option for improving PHT. We investigated whether the addition of rifaximin to pro-pranolol therapy can improve hepatic venous pressure gradient (HVPG) response. Methods: Sixty-four cirrhosis patients were randomly assigned to propranolol monotherapy (n=48) versus rifaximin and propranolol combination therapy (n=16). Baseline and post-Treatment HVPG values, BT-related markers (lipopolysaccharide [LPS], LPS-binding protein [LBP], interleukin-6 [IL-6], and tumor necrosis factor α [TNF-α]), serological data, and adverse event data were collected. HVPG response rate was the primary endpoint. Results: Combination therapy was associated with better HVPG response rates than monotherapy (56.2% vs 87.5%, p=0.034). In combination therapy, posttreatment BT-related markers were significantly decreased (LPS, p=0.005; LBP, p=0.005; IL-6, p=0.005; TNF-α, p=0.047). Conclusions: Rifaximin combination therapy showed an additive effect in improving PHT compared to propranolol monotherapy. These pilot data suggest that the addition of rifaximin to NSBBs could be a good therapeutic option for overcoming the limited effectiveness of NSBBs.

AB - Background/Aims: Non-selective beta blockers (NSBBs) are currently the only accepted regimen for preventing portal hypertension (PHT)-related complications. However, the effect of NSBBs is insufficient in many cases. Bacterial translocation (BT) is one of the aggravating factors of PHT in cirrhosis; therefore, selective intestinal decontamination by rifaximin is a possible therapeutic option for improving PHT. We investigated whether the addition of rifaximin to pro-pranolol therapy can improve hepatic venous pressure gradient (HVPG) response. Methods: Sixty-four cirrhosis patients were randomly assigned to propranolol monotherapy (n=48) versus rifaximin and propranolol combination therapy (n=16). Baseline and post-Treatment HVPG values, BT-related markers (lipopolysaccharide [LPS], LPS-binding protein [LBP], interleukin-6 [IL-6], and tumor necrosis factor α [TNF-α]), serological data, and adverse event data were collected. HVPG response rate was the primary endpoint. Results: Combination therapy was associated with better HVPG response rates than monotherapy (56.2% vs 87.5%, p=0.034). In combination therapy, posttreatment BT-related markers were significantly decreased (LPS, p=0.005; LBP, p=0.005; IL-6, p=0.005; TNF-α, p=0.047). Conclusions: Rifaximin combination therapy showed an additive effect in improving PHT compared to propranolol monotherapy. These pilot data suggest that the addition of rifaximin to NSBBs could be a good therapeutic option for overcoming the limited effectiveness of NSBBs.

UR - http://www.scopus.com/inward/record.url?scp=85032033874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032033874&partnerID=8YFLogxK

U2 - 10.5009/gnl16478

DO - 10.5009/gnl16478

M3 - Article

C2 - 28651304

AN - SCOPUS:85032033874

VL - 11

SP - 702

EP - 710

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 5

ER -